The historical rank and industry rank for Glenmark Pharmaceuticals's OCF Margin % or its related term are showing as below:
NSE:GLENMARK'
s OCF Margin % Range Over the Past 10 Years
Min: -6.3 Med: 9.79 Max: 20.61
Current: 20.61
During the past 13 years, the highest OCF Margin % of Glenmark Pharmaceuticals was 20.61%. The lowest was -6.30%. And the median was 9.79%.
NSE:GLENMARK's OCF Margin % is ranked better than 78.36% of 961
companies
in the Drug Manufacturers industry
Industry Median: 9.94
vs NSE:GLENMARK: 20.61
Glenmark Pharmaceuticals OCF Margin % Related Terms
Glenmark Pharmaceuticals OCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:GLENMARK vs ZTS, UTHR: OCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Glenmark Pharmaceuticals's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glenmark Pharmaceuticals OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Glenmark Pharmaceuticals's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Glenmark Pharmaceuticals's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glenmark Pharmaceuticals (NSE:GLENMARK) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Glenmark Pharmaceuticals and its competitors. According to the industry distribution chart, Glenmark Pharmaceuticals ranks #208 out of 961 companies in the Drug Manufacturers industry, placing it in the top 21.6%.
Is Glenmark Pharmaceuticals' OCF Margin % too high?
Glenmark Pharmaceuticals' current OCF Margin % is 0.00%. Based on the distribution chart, Glenmark Pharmaceuticals ranks #208 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Glenmark Pharmaceuticals has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Glenmark Pharmaceuticals' OCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Glenmark Pharmaceuticals ranks #208 out of 961 companies for OCF Margin %. This places Glenmark Pharmaceuticals in the top 22% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 9.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.94, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Glenmark Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Glenmark Pharmaceuticals's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glenmark Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Glenmark Pharmaceuticals (NSE:GLENMARK) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,985.75, compared to a current price of ₹2,161.90 — trading 8.9% above its estimated fair value. The current OCF Margin % is 0.00%. Glenmark Pharmaceuticals' overall GF Score™ is 85/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Glenmark Pharmaceuticals (NSE:GLENMARK), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glenmark Pharmaceuticals (NSE:GLENMARK) Overvalued in 2026?
Based on GuruFocus' analysis, Glenmark Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹2,161.90 is trading 8.9% above its estimated GF Value™ of ₹1,985.75.
GuruFocus considers Glenmark Pharmaceuticals to be Fairly Valued.
Key valuation signals for NSE:GLENMARK:
OCF Margin %: 0.00%
GF Value™: ₹1,985.75 vs. price of ₹2,161.90 (8.9% above fair value)
No single metric tells the full story. See the NSE:GLENMARK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe and the Rest of the world.
85GF Score
Get the complete analysis for NSE:GLENMARK
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLENMARK has been successfully added to your 
